Compare ARK Genomic Revolution ETF (ARKG) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Enbridge Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Enbridge Inc trades at $54.82 (market cap $118.96B). The key difference: Enbridge Inc pays a 5.14% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Enbridge Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | ENB | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $43.57 | $58.04 |
52-Week Low | $23.09 | $44.55 |
Market Cap | — | $118.96B |
Enterprise Value | — | $199.76B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Enbridge (ENB) trades at $54.66, up 0.13% on the day, with a neutral technical signal and mixed earnings history. The company reported strong revenue growth to $65.19B in 2025 and maintains a 10% net income margin. Recent news highlights its 5.1% dividend yield and AI-driven growth projects, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains balanced with steady cash flow and dividend appeal offset by high debt levels and earnings volatility. Key opportunities include infrastructure expansion and high yield, while risks involve interest rate sensitivity and execution challenges in capital projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
